CompanyHELPNasdaqToronto, A6

Cybin Inc.

Cybin Inc., operating as Helus Pharma, develops proprietary NSAs (synthetic serotonin pathway activators) for mental health.

SEC EDGAR ClinicalTrials.gov helus.com

10-KSep 25Latest SEC filing

Sep 21Latest story

September 2026

Helus Pharma CEO to join TD Cowen neuropsychiatry summit fireside chat

Sep 21PeopleCybin Inc.

Cybin's Helus Pharma to join three investor conferences in New York in September 2026

Sep 10PeopleCybin Inc.

Cybin discloses Form D for stock option grant tied to $11.78 strike price

Sep 1FinancingCybin Inc.

August 2026

Cybin files two Form D notices for equity awards to executives and directors

Aug 19FinancingCybin Inc.

Helus Pharma names Intra-Cellular veterans to leadership and advisory roles

Aug 18PeopleCybin Inc.

Helus Pharma names Michael Halstead CEO ahead of HLP003 Phase 3 readout

Aug 10PeopleCybin Inc.

July 2026

Helus Pharma completes enrollment in Phase 3 APPROACH study of HLP003 for MDD

Jul 21Trial updateCybin Inc.

Cybin discloses two Form D filings for stock options and RSUs

Jul 15FinancingCybin Inc.

June 2026

Cybin's Helus Pharma reports FY2026 results, Phase 3 MDD trial past 88% enrollment

Jun 29Clinical readoutCybin Inc.